PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma

Expert Review of Clinical Pharmacology
Maria Rita GaiserIsaac Brownell

Abstract

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that lacks durable responses to traditional chemotherapy. Areas covered: After MCC was shown to be an immunogenic tumor, small trials revealed high objective response rates to PD-1/PD-L1 checkpoint inhibitors. The JAVELIN Merkel 200 (NCT02155647) trial tested the use of avelumab, a human IgG1 monoclonal antibody against PD-L1, in metastatic MCC. Avelumab recently became the first approved drug for metastatic MCC. Expert commentary: By conducting broad phase I studies assessing the safety of avelumab and a small phase II study demonstrating efficacy in this rare orphan tumor type, avelumab gained accelerated approval for the treatment of metastatic MCC. Additional studies are needed to determine how the antibody-dependent cellular cytotoxicity (ADCC) competent Fc region of avelumab contributes to disease control. Remaining questions: Longer follow-up will determine the durability of checkpoint blockade in controlling metastatic MCC. Additional studies will assess the utility and safety of adjuvant checkpoint blockade in patients with excised MCC. How to increase response rates by combining PD-1/PD-L1 blockade with other treatment approaches needs to ...Continue Reading

References

Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P T TaiJ Gilchrist
Dec 22, 2004·Journal of Surgical Oncology·Nicole C Hodgson
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Jan 19, 2008·Science·Huichen FengPatrick S Moore
Feb 28, 2008·Current Opinion in Oncology·Patricia Tai
May 27, 2008·Nature Reviews. Immunology·Weiping Zou, Lieping Chen
Jul 18, 2008·The Journal of Investigative Dermatology·Jürgen C BeckerDavid Schrama
Jul 25, 2008·The Journal of Investigative Dermatology·Kelly M GarneskiPaul Nghiem
Dec 2, 2008·Expert Opinion on Drug Metabolism & Toxicology·Jacques Descotes, Aurore Gouraud
Mar 18, 2011·International Journal of Cancer. Journal International Du Cancer·Roland HoubenDavid Schrama
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kelly G PaulsonPaul Nghiem
Jul 15, 2011·Molecular Immunology·Nassima MessalDaniel Olive
Aug 16, 2011·The Journal of Clinical Investigation·Masahiro ShudaPatrick S Moore
Sep 20, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·D Schrama, J C Becker
Oct 28, 2011·Journal of the American Academy of Dermatology·Matthew FooteMichael Poulsen
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Nov 30, 2012·The Journal of Investigative Dermatology·Kelly G PaulsonPaul Nghiem
Mar 12, 2013·Journal of Skin Cancer·Laura Desch, Rainer Kunstfeld
Mar 26, 2014·International Journal of Radiation Oncology, Biology, Physics·Christopher A Barker, Michael A Postow
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Apr 30, 2014·Cancer Immunology Research·Christopher A BarkerJedd D Wolchok
Jun 20, 2014·JAMA Dermatology·Danny R YouldenPeter D Baade
Aug 15, 2014·Cancer Immunology Research·Kelly G PaulsonPaul Nghiem
Sep 6, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·Ata S Moshiri, Paul Nghiem
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberMary L Disis
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Aug 5, 2015·Cancer Research·Paul William HarmsArul M Chinnaiyan
Aug 11, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Celeste LebbeClaus Garbe
Sep 1, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Therese PhillipsXiaoling Zhang

❮ Previous
Next ❯

Citations

May 8, 2019·Immunotherapy·Giandomenico RovielloNavid Sobhani
Sep 12, 2020·Journal for Immunotherapy of Cancer·Leylah DrusboskySandeep Bobby Reddy
Sep 22, 2020·Expert Opinion on Biological Therapy·Gerhard Hamilton
Sep 29, 2020·Drug Design, Development and Therapy·Leilei AiXiaochun Yang
Apr 17, 2020·Cancers·Magali BoyerCatherine Alix-Panabières
Mar 25, 2021·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Katja DickeThomas Dirschka
Apr 11, 2021·Cancer Gene Therapy·Coral García-FernándezSalvador Borrós

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Aric ColungaPaul Nghiem
JAAPA : Official Journal of the American Academy of Physician Assistants
Sally Becker
© 2022 Meta ULC. All rights reserved